Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04519957 · ClinicalTrials.gov registry record
Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)
A clinical trial, sponsored by COMPASS Pathways.
- Completed
- Registry status
- 66
- Enrollment target
NCT04519957 is a clinical trial that has completed, run by COMPASS Pathways. The registered enrollment target is 66 participants.
The verdict
NCT04519957 has completed, sponsored by COMPASS Pathways.
- COMPLETED
- Registry status
- 66 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS) over a total of 52 weeks (compared across the 1 mg, 10 mg and 25 mg psilocybin groups from COMP 001).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2020-07-20 |
| Est. Completion | 2022-08-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04519957
The ClinicalTrials.gov registry entry for NCT04519957 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is COMPASS Pathways, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04519957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04519957 about?
NCT04519957 is a clinical study titled "Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)". The primary objective of this study is to assess the long-term efficacy of psilocybin with respect to use of new antidepressant treatment, hospitalisations for depression, suicidality, and depressive severity rated using the Montgomery and Asberg Depression Rating Scale (MADRS) over a total of 52 we...
What is the current status of trial NCT04519957?
This trial is currently completed. The enrollment target is 66 participants. The study started on 2020-07-20. Estimated completion is 2022-08-11.
Who is sponsoring clinical trial NCT04519957?
This trial is sponsored by COMPASS Pathways, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.